MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
22 juin 2023 06h05 HE
|
MannKind
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Time-in-range during waking...
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
11 juin 2023 08h05 HE
|
MannKind
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides...
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
24 mai 2023 08h30 HE
|
MannKind
DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
10 mai 2023 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
09 mai 2023 20h21 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the...
Mannkind Corporation Reports 2023 First Quarter Financial Results
09 mai 2023 16h00 HE
|
MannKind
1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of...
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
02 mai 2023 17h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a...
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
27 mars 2023 16h05 HE
|
MannKind
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 17h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
23 févr. 2023 16h00 HE
|
MannKind
2022 Total Revenues of $100 million; +32% vs. 20212022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021$173...